Fundraising Fox

RheumaGen

Denver, US · Founded 2022 · Delaware corporation

Biotech

Founders & leadership

JB
James Brian Hart, Jr.Executive Officer
BM
Brian M. FreedExecutive Officer, Director
GL
Gregory L. AndrewsDirector
RA
Richard Anthony Freed, IIIExecutive Officer, Director
RK
Ryan Kane HartExecutive Officer

Reported raises · per SEC filings

Form D private placements
▶$4.9MraisedApr 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan Kane HartExecutive Officer
  • Bobak Robert MozayeniExecutive Officer
  • Bruce Michael GoodwinDirector
  • Thomas Matthew FratacciDirector
  • Brian Matthew FreedExecutive Officer
  • Richard Anthony Freed, IIIExecutive Officer, Director
  • James Brian Hart, Jr.Executive Officer
Offering amount
$15M
Amount sold
$4.9M
Proceeds to insiders
$3M
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$700KraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce Michael GoodwinDirector
  • James Brian Hart, Jr.Executive Officer
  • Bobak Robert MozayeniExecutive Officer
  • Ryan Kane HartExecutive Officer
  • Thomas Matthew FratacciDirector
  • Brian Matthew FreedExecutive Officer
  • Richard Anthony Freed, IIIExecutive Officer, Director
Offering amount
$700K
Amount sold
$700K
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedMay 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James Brian Hart, Jr.Executive Officer
  • Brian M. FreedExecutive Officer, Director
  • Gregory L. AndrewsDirector
  • Richard Anthony Freed, IIIExecutive Officer, Director
  • Ryan Kane HartExecutive Officer
Offering amount
$300K
Amount sold
$300K
Minimum investment
$300K
Proceeds to insiders
$243.7K
First sale
May 2023
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James Brian Hart, Jr.Executive Officer
  • Ryan Kane HartExecutive Officer
  • Gregory L. AndrewsDirector
  • Richard Anthony Freed, IIIExecutive Officer, Director
  • Brian M. FreedExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
Minimum investment
$2M
Proceeds to insiders
$970.2K
First sale
Oct 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.